普乐安联合琥珀酸索利那新治疗良性前列腺增生术后膀胱过度活动症的效果观察  

Pule'an combined with solifenacin in treatment of overactive bladder patients with benign prostatic hyperplasia after resection

作　　者：叶俊杰 吴琦[1] YE Junjie;WU Qi(Department of Urology,Lishui Municipal People's Hospital,Lishui 323000,China)

机构地区：[1]丽水市人民医院泌尿外科,323000

出　　处：《浙江医学》2024年第11期1183-1186,1196,共5页Zhejiang Medical Journal

基　　金：浙江省医学会临床科研基金项目(2022ZYC-A107)。

摘　　要：目的探讨普乐安联合琥珀酸索利那新治疗良性前列腺增生(BPH)术后膀胱过度活动症(OAB)的临床效果。方法回顾性选取2022年5月至2023年6月在丽水市人民医院行经尿道前列腺钬激光剜除术后发生OAB的60例BPH患者为研究对象,其中普乐安联合琥珀酸索利那新治疗(联合组)31例,仅琥珀酸索利那新治疗(单药组)29例;比较两组患者术后膀胱过度活动症状评分(OABSS)、OAB缓解率(OABSS降低至3分以下且1 d内未明显升高)、残余尿量、生活质量评分(QOL)、国际前列腺症状评分(IPSS)等疗效指标,采用单因素及多因素Cox回归分析OAB缓解的影响因素。结果联合组术后半个月及1个月OABSS均低于单药组(均P<0.05),术后半个月及1个月OAB缓解率均高于单药组(均P<0.05);两组患者术后3个月OABSS、OAB缓解率、残余尿量、QOL、IPSS比较,差异均无统计学意义(均P>0.05)。联合治疗方案(HR=0.562)是OAB缓解的独立保护因素,术后用药前OABSS尿急评分4~5分(HR=2.082)、术后用药前QOL 4~6分(HR=2.180)、吸烟(HR=3.466)是OAB缓解的独立危险因素,差异均有统计学意义(均P<0.05)。结论普乐安联合琥珀酸索利那新治疗能加快缓解BPH患者术后OAB症状,是OAB缓解的独立保护因素。Objective To investigate the efficacy of Pule'an combined with solifenacin succinate in treatment of overactive bladder(OAB)patients with benign prostatic hyperplasia(BPH)after resection.Methods Sixty patients with OAB after holmium laser enucleation of the prostate who were admitted in Lishui Municipal People's Hospital from May 2022 to June 2023 were enrolled in the study,including 31 cases treated with Pule'an and solifenacin succinate(combination group),and 29 cases treated with solifenacin succinate alone(monotherapy group).The overactive bladder symptom score(OABSS),OAB remission rate(OABSS decreased by less than 3 points and did not increase significantly within 1 day),residual urine volume,quality of life score(QOL)and international prostate symptom score(IPSS)were compared between the two groups after treatment.Univariate and multivariate Cox analyses were used to identify factors influencing OAB remission.Results The OABSS score in combination group was lower and OAB remission rate in combination group was higher than those in monotherapy group 0.5,1 month after surgery(all P<0.05).There were no significant differences in OABSS,residual urine volume,QOL,IPSS,and OAB remission rate between the two groups at 3 months after resection(all P>0.05).Combination therapy(HR=0.562)was an independent protective factor for OAB,while OABSS score of 4-5(HR=2.082),preoperative QOL score of 4-6(HR=2.180),and smoking(HR=3.466)were independent risk factors for OAB(all P< 0.05). Conclusion Combination therapy with Pule'an and solifenacin succinate significantly alleviates OAB symptoms and serves as an independent enhancing factor for OAB remission.

关 键 词：普乐安 索利那新 良性前列腺增生 膀胱过度活动症 

分 类 号：R699.8[医药卫生—泌尿科学]